

78% of all chronic wounds contain biofilm¹.
Act with certainty.

 **smith&nephew**
IODOSORB[®]
0.9% Cadexomer Iodine

Supporting healthcare professionals

IODOSORB unique 4 in 1 action overcome multiple barriers to healing, allowing you to take control of chronic wounds:

- Effective deslougher²⁻⁵
- High absorption capacity^{1,3-8}
- Provides sustained release of iodine^{9,10} (*in-vitro*). IODOSORB can last for up to 72 hours.¹¹
- Proven to disrupt and eradicate mature biofilm^{12,13} (*in-vitro*)



To learn more about IODOSORB:  visit www.smith-nephew.com/canada  contact your local Smith & Nephew representative

References 1.MaloneM,et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data.J Wound Care 2017;26:20-25 2.Smith & Nephew Research Centre Work Report #WRP- TSG015-07-003. 3..Phillips, P. L. et al., Effects of Antimicrobial Agents on an (in vitro) Biofilm Model of Skin Wounds. ADVANCES IN WOUND CARE (2010) 1: 299-304. 4.Sundberg J and Meller R. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. Wounds (1997), 9(3): p 68-86. 5.Holloway GA, Johansen KH, Barnes RW et al., Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med, (1989 Jul), 151, p35-38.6.Ormiston MC et al., A randomised comparison of cadexomer iodine and a standard treatment in out-patients with chronic leg ulcers. In Cadexomer Iodine JA Fox, H Fischer eds. (1983) 63-69. 7.Moberg S et al., A randomised trial of cadexomer iodine in decubitus ulcers. J Am Geriatrics Soc. (1983).31 p462-465. 8.Lindsay G et al., A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. Acta Therapeutica (1986) 12, p141-148 9. Drosou A, Falabella A, Kirsner MD. Antiseptics on Wounds: An area of controversy. Wounds (May 2003), Vol 15 no 5, p149-166. 11. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Int J Dermatology (1998) 37: p390-396. 12.Troeng T et al., In Cadexomer iodine. Fox JA, Fischer H (eds) (1983) p43-50.13.Johnson A. A combative healer with no ill effect. IODOSORB in the treatment of infected wounds. Professional Nurse (Oct 1991) p60-64.1 4.Skog E et al., A randomised trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. Br J Dermatology (1983) 109, p77-83. 15. Drolshagen C and Schaffer D. Use of absorbent antimicrobial and viscous hydrogel to manage ulcers secondary to peripheral vascular disease. Poster presented at the (1999) Symposium on Advanced Wound Care, Anaheim. 16. Salman H and Leakey A. A report to Smith & Nephew Medical Ltd. The (in vitro) activity of silver Sulphadiazine and cadexomer iodine against recent clinical isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative staphylococci and Pseudomonas aeruginosa. Report number 194-03-01 (March 2001).17.Mertz PM et al., Can Antimicrobials be effective without impairing wound healing? The evaluation of a cadexomer iodine ointment. Wounds (1994), 6(6), p184-19

Smith & Nephew Inc, 2280 Argenta Rd, Mississauga, ON L5N 6H8, Canada, T1-800-463-7439, F1-800-671-9140 | *Trademark of Smith & Nephew | All Trademarks acknowledged | ©February 2019 Smith & Nephew | IODO-ADS-1902EN (CA88366)